Trial Profile

A multicenter randomized trial to evaluate the antiemetic efficacy of aprepitant for nausea and vomiting associated with chemotherapies for hematopoietic malignancies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aprepitant (Primary) ; Serotonin receptor antagonists
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use

Most Recent Events

10 Dec 2013 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
02 Jun 2013 Primary endpoint 'Complete-clinical-response-rate' has been met.
02 Jun 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com